News | March 17, 2023
Mindset Pharma to defend against lawsuit filed by Reunion Neurosciences
Mindset disagrees with and denies the allegations set forth from Reunion.
Mindset disagrees with and denies the allegations set forth from Reunion.
The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
Doctors at Yashoda Hospitals Hyderabad perform rare operation
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
Subscribe To Our Newsletter & Stay Updated
